Anifrolumab: the new frontier in the treatment of genetic interferonopathies
dc.rights.license | open | en_US |
dc.contributor.author | FREMOND, Marie-Louise | |
dc.contributor.author | DAVID, Clemence | |
hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
dc.contributor.author | RICHEZ, Christophe | |
dc.date.accessioned | 2024-10-16T12:48:46Z | |
dc.date.available | 2024-10-16T12:48:46Z | |
dc.date.issued | 2024-09 | |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/202539 | |
dc.language.iso | EN | en_US |
dc.rights | Attribution-NonCommercial 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
dc.subject.en | Autoimmune diseases | |
dc.subject.en | Inflammation | |
dc.subject.en | Therapeutics | |
dc.title.en | Anifrolumab: the new frontier in the treatment of genetic interferonopathies | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1136/rmdopen-2024-004780 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
dc.identifier.pubmed | 39313304 | en_US |
bordeaux.journal | RMD Open | en_US |
bordeaux.volume | 10 | en_US |
bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
bordeaux.issue | 3 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | CNRS | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-04739859 | |
hal.version | 1 | |
hal.date.transferred | 2024-10-16T12:48:49Z | |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | true | |
dc.rights.cc | CC BY-NC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RMD%20Open&rft.date=2024-09&rft.volume=10&rft.issue=3&rft.au=FREMOND,%20Marie-Louise&DAVID,%20Clemence&RICHEZ,%20Christophe&rft.genre=article |